FindTrial
Sign In

Optimal patient Selection for CArdiac Resynchronisation Therapy using Molecular Imaging

Optimal patient Selection for CArdiac Resynchronisation Therapy using Molecular Imaging - SCART-MI

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38477
Enrollment
91
Registered
2013-07-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure Left ventricular dyssynchrony

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Informed consent obtained -Chronic heart failure; -New York Heart Association functional class II, III or IV; -QRS duration *150 ms for NYHA class II or *120 ms for NYHA class III/IV; -Optimal pharmacological therapy; -Left ventricular ejection fraction *35%.

Exclusion criteria

Exclusion criteria: -Contraindications for implantation of a CRT device; -Age

Design outcomes

Primary

MeasureTime frame
-99mTc-Tetrofosmin(MPS)-based dyssynchrony and infarct burden measurements -123I-metaiodobenzylguanidine(MIBG)-based Heart-to-Mediastinum(H/M)-ratio The main study parameters will be compared to response to CRT as defined by: -Reduction in LVESV * 15%.—

Secondary

MeasureTime frame
-change in innervation and perfusion parameters after CRT -Infarct location as predictor of respons to CRT—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)